{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:45:16Z","timestamp":1783683916563,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National emphasis research and development project","award":["2018YFC1313203"],"award-info":[{"award-number":["2018YFC1313203"]}]},{"name":"National emphasis research and development project","award":["2018YFC1313203"],"award-info":[{"award-number":["2018YFC1313203"]}]},{"name":"National emphasis research and development project","award":["2018YFC1313203"],"award-info":[{"award-number":["2018YFC1313203"]}]},{"name":"The \u201cTumor Targeted Research Special Fund\u201d project of the Institute of Hospital Management of the National Health Commission","award":["WJWYGS-201816"],"award-info":[{"award-number":["WJWYGS-201816"]}]},{"name":"The \u201cTumor Targeted Research Special Fund\u201d project of the Institute of Hospital Management of the National Health Commission","award":["WJWYGS-201816"],"award-info":[{"award-number":["WJWYGS-201816"]}]},{"name":"The \u201cTumor Targeted Research Special Fund\u201d project of the Institute of Hospital Management of the National Health Commission","award":["WJWYGS-201816"],"award-info":[{"award-number":["WJWYGS-201816"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the feasibility, safety and efficacy of concurrent simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab in the treatment of locally advanced esophageal squamous cell cancer (ESCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible patients were histologically proven to have locally advanced ESCC, and were unable to tolerate or refuse concurrent chemoradiotherapy (CCRT). Enrolled patients underwent concurrent SIB-IMRT in combination with nimotuzumab. SIB-IMRT: For the planning target volume of clinical target volume (PTV<jats:sub>-C<\/jats:sub>), the prescription dose was 50.4\u00a0Gy\/28fractions, 1.8\u00a0Gy\/fraction, 5fractions\/week, concurrently, the planning target volume of gross tumor (PTV<jats:sub>-G<\/jats:sub>) undergone an integrated boost therapy, with a prescription dose of 63\u00a0Gy\/28fractions, 2.25\u00a0Gy\/fraction, 5 fractions\/week. Nimotuzumab was administered concurrently with radiotherapy, 200\u00a0mg\/time, on D1, 8, 15, 22, 29, and 36, with a total accumulation of 1200\u00a0mg through intravenous infusion. The primary endpoint of the study was the safety and efficacy of the combined treatment regimen, and the secondary endpoints were 1-year, 2-year, and 3-year local control and survival outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>(1) From December 2018 to August 2021, 35 patients with stage II-IVA ESCC were enrolled and 34 patients completed the full course of radiotherapy and the intravenous infusion of full-dose nimotuzumab. The overall completion rate of the protocol was 97.1%. (2) No grade 4\u20135 adverse events occurred in the entire group. The most common treatment-related toxicity was acute radiation esophagitis, with a total incidence of 68.6% (24\/35). The incidence of grade 2 and 3 acute esophagitis was 25.7% (9\/35) and 17.1% (6\/35), respectively. The incidence of acute radiation pneumonitis was 8.6% (3\/35), including one case each of Grades 1, 2, and 3 pneumonitis. Adverse events in other systems included decreased blood cells, hypoalbuminemia, electrolyte disturbances, and skin rash. Among these patients, five experienced grade 3 electrolyte disturbances during the treatment period (three with grade 3 hyponatremia and two with grade 3 hypokalemia). (3) Efficacy: The overall CR rate was 22.8%, PR rate was 71.4%, ORR rate was 94.2%, and DCR rate was 97.1%.(4) Local control and survival: The 1-, 2-, and 3-year local control (LC) rate, progression-free survival(PFS) rate, and overall survival(OS) rate for the entire group were 85.5%, 75.4%, and 64.9%; 65.7%, 54.1%, and 49.6%; and 77.1%, 62.9%, and 54.5%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The combination of SIB-IMRT and nimotuzumab for locally advanced esophageal cancer demonstrated good feasibility, safety and efficacy. It offered potential benefits in local control and survival. Acute radiation esophagitis was the primary treatment-related toxicity, which is clinically manageable. This comprehensive treatment approach is worthy of further clinical exploration (ChiCTR1900027936).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12427-y","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:01:51Z","timestamp":1717466511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"24","key":"12427_CR1","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593\u20138. https:\/\/doi.org\/10.1056\/NEJM199206113262403.","journal-title":"N Engl J Med"},{"issue":"17","key":"12427_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u201301). Radiation therapy oncology group. JAMA. 1999;281(17):1623\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1623.","journal-title":"JAMA"},{"issue":"5","key":"12427_CR3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94\u201305) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167\u201374. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1167. (PMID: 11870157).","journal-title":"J Clin Oncol"},{"issue":"6","key":"12427_CR4","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.21037\/tcr-21-505","volume":"10","author":"L Wang","year":"2021","unstructured":"Wang L, Wang X, Ren X, et al. Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A). Transl Cancer Res. 2021;10(6):2932\u201343. https:\/\/doi.org\/10.21037\/tcr-21-505.","journal-title":"Transl Cancer Res"},{"issue":"10","key":"12427_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/fon-2020-0969","volume":"17","author":"MA Shah","year":"2021","unstructured":"Shah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021;17(10):1143\u201353. https:\/\/doi.org\/10.2217\/fon-2020-0969.","journal-title":"Future Oncol"},{"key":"12427_CR6","doi-asserted-by":"publisher","unstructured":"Wang W, Li J, Li T, et al. A phaseIII trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2020;38. https:\/\/doi.org\/10.1200\/jco.2020.38.4_suppl.tps475.","DOI":"10.1200\/jco.2020.38.4_suppl.tps475"},{"key":"12427_CR7","doi-asserted-by":"publisher","unstructured":"Wang L, Chen M, Kato K, et al. A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN. J Clin Oncol. 2022;40. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.TPS373.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS373"},{"issue":"1","key":"12427_CR8","doi-asserted-by":"publisher","first-page":"1971418","DOI":"10.1080\/2162402X.2021.1971418","volume":"10","author":"W Zhang","year":"2021","unstructured":"Zhang W, Yan C, Zhang T, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology. 2021;10(1):1971418. https:\/\/doi.org\/10.1080\/2162402X.2021.1971418.","journal-title":"Oncoimmunology"},{"issue":"1","key":"12427_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12885-020-06716-5","volume":"20","author":"H Bando","year":"2020","unstructured":"Bando H, Kotani D, Tsushima T, et al. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer. 2020;20(1):336. https:\/\/doi.org\/10.1186\/s12885-020-06716-5.","journal-title":"BMC Cancer"},{"issue":"5","key":"12427_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/0284186X.2021.1902564","volume":"60","author":"C Li","year":"2021","unstructured":"Li C, Wang X, Wang L, et al. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncol. 2021;60(5):627\u201334. https:\/\/doi.org\/10.1080\/0284186X.2021.1902564.","journal-title":"Acta Oncol"},{"issue":"9","key":"12427_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s00066-021-01894-y","volume":"198","author":"W Lan","year":"2022","unstructured":"Lan W, Lihong L, Chun H, et al. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study. Strahlenther Onkol. 2022;198(9):802\u201311. https:\/\/doi.org\/10.1007\/s00066-021-01894-y.","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"12427_CR12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41416-023-02388-7","volume":"129","author":"X Meng","year":"2023","unstructured":"Meng X, Zheng A, Wang J, et al. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial. Br J Cancer. 2023;129(11):1787\u201392. https:\/\/doi.org\/10.1038\/s41416-023-02388-7.","journal-title":"Br J Cancer"},{"issue":"4","key":"12427_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/cas.12894","volume":"107","author":"M Lu","year":"2016","unstructured":"Lu M, Wang X, Shen L, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Cancer Sci. 2016;107(4):486\u201390. https:\/\/doi.org\/10.1111\/cas.12894.","journal-title":"Cancer Sci"},{"issue":"8","key":"12427_CR14","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.21037\/jtd.2018.07.48","volume":"10","author":"SY Park","year":"2018","unstructured":"Park SY, Kim DJ, Suh JW, et al. Comparison of the 11th Japanese classification and the AJCC 7th and 8th staging systems in esophageal squamous cell carcinoma patients. J Thorac Dis. 2018;10(8):5039\u201346. https:\/\/doi.org\/10.21037\/jtd.2018.07.48.","journal-title":"J Thorac Dis"},{"key":"12427_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228\u201347.","journal-title":"Eur J Cancer"},{"issue":"8","key":"12427_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/15384047.2019.1598760","volume":"20","author":"W Jing","year":"2019","unstructured":"Jing W, Yan W, Liu Y, et al. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Biol Ther. 2019;20(8):1121\u20136. https:\/\/doi.org\/10.1080\/15384047.2019.1598760.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"12427_CR17","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","volume":"28","author":"Y Xu","year":"2022","unstructured":"Xu Y, Dong B, Zhu W, et al. A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2022;28(9):1792\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3843.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"12427_CR18","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/JCO.20.03697","volume":"39","author":"MCCM Hulshof","year":"2021","unstructured":"Hulshof MCCM, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021;39(25):2816\u201324. https:\/\/doi.org\/10.1200\/JCO.20.03697.","journal-title":"J Clin Oncol"},{"issue":"11","key":"12427_CR19","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/jamaoncol.2019.2809","volume":"5","author":"D Chen","year":"2019","unstructured":"Chen D, Menon H, Verma V, et al. Results of a Phase 1\/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019;5(11):1597\u2013604. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2809.","journal-title":"JAMA Oncol"},{"key":"12427_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.10.005","volume":"88","author":"JG de Castro","year":"2018","unstructured":"de Castro JG, Segalla JG, de Azevedo SJ, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial. Eur J Cancer. 2018;88:21\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.005.","journal-title":"Eur J Cancer"},{"issue":"11","key":"12427_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00066-014-0636-y","volume":"190","author":"WW Yu","year":"2014","unstructured":"Yu WW, Zhu ZF, Fu XL, et al. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol. 2014;190(11):979\u201386.https:\/\/doi.org\/10.1007\/s00066-014-0636-y.","journal-title":"Strahlenther Onkol"},{"issue":"Supplement","key":"12427_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0973-1482.191640","volume":"12","author":"Y Xu","year":"2016","unstructured":"Xu Y, Wang Z, Liu G, et al. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience. J Cancer Res Ther. 2016;12(Supplement):82\u20138. https:\/\/doi.org\/10.4103\/0973-1482.191640.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"12427_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.radonc.2014.12.007","volume":"114","author":"W Yu","year":"2015","unstructured":"Yu W, Cai XW, Liu Q, et al. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET\/CT for esophageal cancer. Radiother Oncol. 2015;114(2):195\u2013200. https:\/\/doi.org\/10.1016\/j.radonc.2014.12.007.","journal-title":"Radiother Oncol"},{"issue":"8","key":"12427_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2174\/1568009623666230315145937","volume":"23","author":"N Yu","year":"2023","unstructured":"Yu N, Cheng G, Li J, et al. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study. Curr Cancer Drug Targets. 2023;23(8):653\u201362. https:\/\/doi.org\/10.2174\/1568009623666230315145937.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"12427_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.21147\/j.issn.1000-9604.2021.01.06","volume":"33","author":"X Yang","year":"2021","unstructured":"Yang X, Zhai Y, Bi N, et al. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. Chin J Cancer Res. 2021;33(1):53\u201360. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.01.06.","journal-title":"Chin J Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12427-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12427-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12427-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:02:15Z","timestamp":1717466535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12427-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12427"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12427-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the fourth hospital of Hebei medical university ethics committee. (ChiCTR1900027936). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"679"}}